Dietary restriction increases protective gut bacteria to rescue lethal methotrexate-induced intestinal toxicity

Gut Microbes. 2020 Nov 9;12(1):1714401. doi: 10.1080/19490976.2020.1714401. Epub 2020 Jan 26.

Abstract

Methotrexate (MTX) is a typical chemotherapeutic drug that is widely used in the treatment of various malignant diseases as well as autoimmune diseases, with gastrointestinal toxicity being its most prominent complication which could have a significant effect on the prognosis of patients. Yet effective ways to alleviate such complications remains to be explored. Here we show that 30% dietary restriction (DR) for 2 weeks dramatically increased the survival rate of 2-month-old female mice after lethal-dose MTX exposure. DR significantly reduced intestinal inflammation, preserved the number of basal crypt PCNA-positive cells, and protected the function of intestinal stem cells (ISCs) after MTX treatment. Furthermore, ablating intestinal microbiota by broad-spectrum antibiotics completely eliminated the protective effect achieved by DR. 16S rRNA gene deep-sequencing analysis revealed that short-term DR significantly increased the Lactobacillus genus, with Lactobacillus rhamnosus GG gavage partially mimicking the rescue effect of DR on the intestines of ad libitum fed mice exposed to lethal-dose MTX. Together, the current study reveals that DR could be a highly effective way to alleviate the lethal injury in the intestine after high-dose MTX treatment, which is functionally mediated by increasing the protective intestinal microbiota taxa in mice. Keywords: Dietary restriction, Methotrexate, Gut microbiota, Intestinal stem cells, intestinal toxicity.

Keywords: Dietary restriction; gut microbiota; intestinal stem cells; intestinal toxicity; methotrexate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Antimetabolites, Antineoplastic / toxicity*
  • Caloric Restriction / methods*
  • Female
  • Gastrointestinal Microbiome / drug effects*
  • Gastrointestinal Microbiome / physiology
  • Humans
  • Inflammation / prevention & control
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / microbiology
  • Intestinal Mucosa / pathology*
  • Lacticaseibacillus rhamnosus / metabolism
  • Methotrexate / toxicity*
  • Mice
  • Mice, Inbred C57BL
  • Probiotics / pharmacology*
  • RNA, Ribosomal, 16S / genetics

Substances

  • Anti-Bacterial Agents
  • Antimetabolites, Antineoplastic
  • RNA, Ribosomal, 16S
  • Methotrexate

Grants and funding

This work was supported by the National Natural Science Fund of China [NSFC-81660520, NSFC-81660244, NSFC-81860027, NSFC-81960267, NSFC-81460030 and NSFC-81770221], and the Jiangxi Provincial Nature Science Foundation [20171ACB21060, 20181BAB205060, and 2018ACB21034],